Início › Leucemia Mieloide Aguda › Arkansas
Ensaios clínicos de Leucemia Mieloide Aguda em Arkansas
13 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Arkansas.
Cidades em Arkansas
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Arkansas at Little Rock, Little Rock
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Arkansas Children's Hospital, Little Rock
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Arkansas Children's Hospital, Little Rock
RecrutandoFase 3
Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Arkansas Children's Hospital, Little Rock
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Arkansas Children's Hospital, Little Rock
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Arkansas Children's Hospital, Little Rock
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Arkansas Children's Hospital, Little Rock
RecrutandoFase 1
Até 21 anos · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05101551Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.